However, a recent report indicated that the use of PD-1 antibody (Nivolumab) in indolent types of ATL patients resulted in disease progression [54], suggesting an anti-tumor role of the PD-1/PD-L1 pathway at indolent stages of ATL. The gene discussed is PDCD1; the disease is neoplasm.